查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1869623

多形性胶质母细胞瘤治疗市场规模、份额和趋势分析报告：按疗法、最终用途、地区和细分市场预测（2025-2033 年）

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

多形性胶质母细胞瘤治疗市场摘要

2024年全球多形性胶质母细胞瘤治疗市场规模估计为37.2亿美元，预计2033年将达到78.7亿美元。

预计从 2025 年到 2033 年，该行业将以 8.68% 的复合年增长率成长。多形性胶质母细胞瘤 (GBM) 的盛行率不断上升及其带来的重大临床负担是 GBM 治疗行业的关键驱动因素。

由于诊断能力的提高和病例数量的大幅增加，胶质母细胞瘤（GBM）的发生率在全球范围内持续上升。尤其令人担忧的是，随着老龄化的增长，GBM在高龄化社会中的影响日益加剧。随着全球老年人口的持续增长，预计GBM病例数将继续增加，这将给医疗保健系统带来更大的压力，并凸显出对更有效治疗方法的迫切需求。

来自世界各地医疗机构的数据凸显了胶质母细胞瘤（GBM）日益加重的临床负担。例如，新加坡百汇癌症中心在2024年12月报告称，该国每年新增约100例GBM病例，凸显了该国先进的神经肿瘤基础设施所面临的巨大压力。 GBM患者通常需要接受强化、多学科的治疗，通常包括放射线治疗以及术后合併放疗和化疗。然而，GBM復发率很高，通常在数月内出现，凸显了现有治疗方法的限制。该中心的报告强调了持续推进个人化医疗的重要性，特别是透过整合基因组学和免疫疗法，以应对GBM治疗的复杂性。

此外，先进技术在神经外科领域的应用正在改善胶质母细胞瘤（GBM）患者的治疗效果，并进一步扩大新兴市场患者的治疗机会。例如，研究表明，术中磁振造影（Io-MRI）透过提高肿瘤切除率显着提升了手术成功率。 2024年发表于《神经肿瘤学杂誌》（Journal of Neuro-Oncology）的一项研究证实，Io-MRI引导下的手术将肿瘤完全切除率从33.6%提高到49.6%，降低了患者復发率，并延长了无恶化生存期。

该疗法的全球推广也得益于医疗资源的改善和有利的医保报销环境。在多个国家，医疗系统已将TTF纳入医疗保险范围，从而消除了符合条件的患者的经济障碍。据Novocure公司称，截至2024年底，全球已有超过4000名患者使用其Optune Geo TTF系统，其中美国、德国、法国和日本的患者数量尤为突出。不断增长的患者群体表明，无论是在已开发医疗市场还是新兴医疗市场，人们对TTF疗法的临床信心和接受度都在不断提高。此外，该疗法的成功也推动了技术的进一步改进和对胶质母细胞瘤（GBM）以外的新适应症研究。这些趋势共同重塑了治疗格局，并将TTF定位为未来GBM治疗方案的关键组成部分。

目录

第一章调查方法和范围

第二章执行摘要

3. 多形性胶质母细胞瘤治疗市场的变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析

第四章 多形性胶质母细胞瘤治疗市场：依疗法分類的业务分析

  • 按疗法分類的市场份额，2024 年和 2033 年
  • 治疗细分仪表板
  • 按疗法分類的市场规模、预测和趋势分析，2021-2033年
  • 外科手术
  • 放射治疗
  • 化疗
  • 标靶治疗（Bevacizumab）

5. 多形性胶质母细胞瘤治疗市场：依最终用途分類的业务分析

  • 按最终用途分類的市场份额，2024 年和 2033 年
  • 最终用户细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析，2021-2033年
  • 医院
  • 诊所/门诊中心
  • 门诊手术中心
  • 其他的

第六章 多形性胶质母细胞瘤治疗市场：各国估算与趋势分析

  • 2024 年及 2033 年各国市场
  • 各国市场概览
  • 市场规模及预测趋势分析（2021-2033）：
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • Merck &Co., Inc.
    • Teva Pharmaceutical
    • Sun Pharma
    • Amneal Pharmaceuticals
    • F. Hoffmann-La Roche Ltd.
    • Amgen, Inc.
    • Pfizer Inc.
    • Arbor Pharmaceuticals（Azurity）
    • Karyopharm Therapeutics, Inc.
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 3.72 billion in 2024 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.68% from 2025 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The incidence of GBM is steadily increasing worldwide, driven by both improved diagnostic capabilities and a genuine rise in the number of cases. Particularly concerning is the increasing impact of GBM on aging populations, as the risk of developing the disease escalates with age. With the global geriatric population continuing to grow, the number of GBM cases is projected to increase, placing additional strain on healthcare systems and underscoring the urgent need for more effective treatment options.

Data from healthcare institutions around the world highlight the growing clinical burden of GBM. For instance, in December 2024, Parkway Cancer Centre in Singapore reported approximately 100 new GBM cases annually, emphasizing the significant strain on the country's advanced neuro-oncology infrastructure. GBM patients typically require intensive, multidisciplinary care, involving surgery followed by concurrent radiotherapy and chemotherapy. However, relapses are common within months, highlighting the limitations of current treatment approaches. The center's report underscores the importance of continued advancements in personalized medicine, particularly through the integration of genomics and immunotherapies, to address the complexities of GBM treatment.

Moreover, the integration of advanced technologies in neurosurgery is improving GBM patient outcomes, further boosting treatment access in emerging markets. For example, studies have shown that intraoperative MRI (Io-MRI) significantly enhances surgery success by improving tumor resection rates. A 2024 study published in the Journal of Neuro-Oncology found that Io-MRI-assisted surgeries increased gross total resection rates from 33.6% to 49.6%, with patients experiencing lower recurrence rates and longer progression-free survival.

The therapy's growing global adoption is also being driven by improved access and supportive reimbursement environments. In several countries, health systems have incorporated TTF into covered treatment options, removing financial barriers for eligible patients. By the end of 2024, Novocure reported over 4,000 active patients on its Optune Gio TTF system globally, with significant user numbers in the U.S., Germany, France, and Japan. This growing patient base demonstrates the expanding clinical confidence and acceptance of TTF therapy across both developed and emerging healthcare markets. Additionally, the therapy's success is encouraging further technological refinements and research into new applications beyond GBM. Together, these trends are reshaping the therapeutic landscape, making TTF a key component of future GBM treatment approaches.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end-use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Lomustine
    • Carmustine Wafers
    • Other
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics / Outpatient Centers
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Temozolomide
      • 4.6.2.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Lomustine
      • 4.6.3.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Carmustine Wafers
      • 4.6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Other
      • 4.6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy (Bevacizumab)
    • 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End-Use Business Analysis

  • 5.1. End-Use Market Share, 2024 & 2033
  • 5.2. End-Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Clinics / Outpatient Centers
    • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Ambulatory Surgical Centers
    • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Countries Estimates & Trend Analysis

  • 6.1. Country Market Share Analysis, 2024 & 2033
  • 6.2. Country Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
    • 6.3.1. U.S.
      • 6.3.1.1. Key Country Dynamics
      • 6.3.1.2. Target Disease Prevalence
      • 6.3.1.3. Regulatory Framework
      • 6.3.1.4. Reimbursement Framework
      • 6.3.1.5. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Framework
      • 6.3.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Framework
      • 6.3.3.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. UK Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Framework
      • 6.4.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Framework
      • 6.4.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Framework
      • 6.4.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Reimbursement Framework
      • 6.4.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Target Disease Prevalence
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Reimbursement Framework
      • 6.4.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Middle East and Africa
    • 6.7.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Target Disease Prevalence
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Reimbursement Framework
      • 6.7.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Target Disease Prevalence
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Reimbursement Framework
      • 6.7.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Merck & Co., Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Teva Pharmaceutical
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sun Pharma
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Amneal Pharmaceuticals
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amgen, Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Pfizer Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Arbor Pharmaceuticals (Azurity)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Karyopharm Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5. Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 6. North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8. North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 9. U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10. U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 11. Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12. Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 13. Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14. Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 15. Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17. Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 18. UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19. UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 20. Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21. Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 22. France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23. France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 24. Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25. Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 26. Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27. Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 28. Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29. Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 30. Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31. Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 32. Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33. Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD
  • Table 36. Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 37. Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38. Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 39. China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40. China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 41. India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42. India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 43. Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44. Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 45. South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46. South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 47. Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48. Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 49. Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51. Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 52. Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53. Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 54. Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55. Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 59. South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60. South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 63. UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64. UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 65. Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66. Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Glioblastoma multiforme treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end-use segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Pharmaceutical market value, 2024 (USD billion)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Porter's five force analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 Glioblastoma multiforme treatment market: By treatment: Key takeaways
  • Fig. 16 Glioblastoma multiforme treatment market, By treatment: market share, 2024 & 2033
  • Fig. 17 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 18 Radiation therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 20 Temozolomide market, 2021 - 2033 (USD Million)
  • Fig. 21 Lomustine settings market, 2021 - 2033 (USD Million)
  • Fig. 22 Carmustine wafers market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 25 Tumor treating field (TTF) therapy market, 2021 - 2033 (USD Million)
  • Fig. 26 Glioblastoma multiforme treatment market: By End Use key takeaways
  • Fig. 27 Glioblastoma multiforme treatment market, By End Use: market share, 2024 & 2033
  • Fig. 28 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 29 Clinics / Outpatient Centers market, 2021 - 2033 (USD Million)
  • Fig. 30 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 31 Others market, 2021 - 2033 (USD Million)
  • Fig. 32 Glioblastoma multiforme treatment market revenue, by region, 2024 & 2033 (USD Million)
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. Glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Regulatory framework
  • Fig. 43 Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Japan glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 China glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Regulatory details: China
  • Fig. 49 Exclusivity formula
  • Fig. 50 Key country dynamics
  • Fig. 51 India glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Registration details: India
  • Fig. 53 Key country dynamics
  • Fig. 54 Australia glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Contribution of PBS by disease
  • Fig. 56 Key country dynamics
  • Fig. 57 Thailand glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 South Korea glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Reimbursement scenario
  • Fig. 61 Rest of Asia Pacific glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Argentina regulatory details
  • Fig. 63 Reimbursement scenario in Argentina
  • Fig. 64 Rest of Latin America glioblastoma multiforme treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 South Africa glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Regulatory framework: South Africa
  • Fig. 69 Key country dynamics
  • Fig. 70 Saudi Arabia glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia pharmaceuticals regulation details
  • Fig. 72 Key country dynamics
  • Fig. 73 UAE glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Kuwait glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 76 Regulatory framework: Kuwait
  • Fig. 77 Rest of MEA glioblastoma multiforme treatment market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 78 Market participant categorization
  • Fig. 79 Strategic framework